Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 10/20 | 0.50 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 7/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27172482 | 1.00 | REN (0.50) | RENSRCNTSR2NTSR1SORT1 | |
| SCHEMBL27204936 | 1.00 | REN (0.50) | RENSRCNTSR2NTSR1SORT1 | |
| SCHEMBL27172513 | 1.00 | REN (0.50) | RENSRCNTSR2NTSR1SORT1 | |
| SCHEMBL27204866 | 0.91 | ACE (0.46) | RENSRCNTSR2NTSR1SORT1 | |
| SCHEMBL27172496 | 0.91 | ACE (0.46) | RENSRCNTSR2NTSR1SORT1 | |
| SCHEMBL27172503 | 0.91 | ACE (0.46) | RENSRCNTSR2NTSR1SORT1 | |
| SCHEMBL27204970 | 0.91 | ACE (0.46) | RENSRCNTSR2NTSR1SORT1 | |
| SCHEMBL31104091 | 0.89 | REN (0.58) | RENNTSR2NTSR1SORT1 | |
| SCHEMBL27172484 | 0.88 | NTSR2 (0.43) | RENSRCNTSR2NTSR1SORT1 | |
| SCHEMBL27172507 | 0.88 | NTSR2 (0.43) | RENSRCNTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294569-A1 | MODULATORS OF SORTILIN ACTIVITY | VESPER BIO APS (DK) | 2024-09-05 | — | — | US | claimed |
| EP-4337674-A2 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2024-03-20 | — | — | EP | claimed |
| EP-4089102-A1 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2022-11-16 | — | — | EP | claimed |
| US-20240294569-A1 | MODULATORS OF SORTILIN ACTIVITY | VESPER BIO APS (DK) | 2024-09-05 | — | — | US | disclosed |
| EP-4337674-A2 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2024-03-20 | — | — | EP | disclosed |
| EP-4089102-A1 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294569-A1 | MODULATORS OF SORTILIN ACTIVITY | SORT1, SCARB1, NPC1 | REN 956/4885SRC 2401/4885NTSR2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.